Entera Bio Ltd.
ENTX evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $465.8M
- Lead Asset:
- eb612 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ENTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENTX
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing oral peptide therapies, with a lead program (EB613) in Phase 3 for osteoporosis and a recent $275M private placement extending its cash runway into 2030.
Key risk: Funding dependency
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$465.8M
Cash Runway
—
Lead Asset
eb612 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial for Entera Bio Ltd..
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing oral peptide therapies, with a lead program (EB613) in Phase 3 for osteoporosis and a recent $275M private placement extending its cash runway into 2030.
- Cash & equivalents of $11.3M as of 2026-06-30 [sec].
- Total revenue of $0.0M and net income of -$7.3M as of 2026-06-30 [sec].
- Shareholders' equity of $7.3M as of 2026-06-30 [sec].
- Accumulated deficit of $136.2M as of June 30, 2026 [sec_mda · as of 2026-08-07].
- July 2026 private placement raised $275M gross proceeds, extending cash runway into 2030 [news · published 2026-07-27].
What works
- The July 2026 private placement significantly strengthened financial position, providing capital to execute the current operating plan into 2030 [sec_mda · as of 2026-08-07].
- If all outstanding warrants are exercised for cash, the company would receive additional proceeds of approximately $22.3 million [sec_mda · as of 2026-08-07].
- The company has a lead product candidate, EB613, advancing to a Phase 3 registrational program for osteoporosis [news · published 2026-07-27].
What to weigh
- The company has incurred significant operating losses and negative cash flows, with an accumulated deficit of $136.2M as of June 30, 2026 [sec_mda · as of 2026-08-07].
- Operating losses were $8.1 million for the six months ended June 30, 2026, compared to $5.2 million for the same period in 2025 [sec_mda · as of 2026-08-07].
- The successful development of product candidates is highly uncertain, and the company cannot reasonably estimate the timing or costs to complete development [sec_mda · as of 2026-05-08].
- The company expects operating expenses to increase significantly as it advances the Phase 3 program for EB613 and other R&D activities [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash, cash equivalents and restricted cash of $18.4 million”
SEC MD&A · August 7, 2026
Accumulated deficit as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $136.2 million.”
SEC MD&A · August 7, 2026
July 2026 private placement gross proceeds
“Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement”
News · July 27, 2026
Operating losses for six months ended June 30, 2026
“2026 and 2025, our operating losses were $8.1 million and $5.2 million, respectively.”
SEC MD&A · August 7, 2026
Risks & what to watch (3)›
Key risks
- Funding dependency — Development of EB613 in osteoporosis is dependent on ability to obtain additional funding, which may not be available on acceptable terms [sec_mda · as of 2026-05-08].
- Uncertain development timeline — Cannot reasonably estimate the nature, timing and costs to complete development of any product candidate [sec_mda · as of 2026-05-08].
- Increasing operating losses — Operating losses increased from $5.2M to $8.1M year-over-year for the six-month period ending June 30 [sec_mda · as of 2026-08-07].
What to watch
- Initiation and progress of the Phase 3 registrational program for EB613 in osteoporosis [news · published 2026-07-27].
- Cash burn rate and whether the $275M private placement extends runway into 2030 as projected [sec_mda · as of 2026-08-07].
- Any updates on the development of EB612 and the collaboration with OPKO [sec_mda · as of 2026-08-07].
- Exercise of outstanding warrants, which could provide up to $22.3 million in additional proceeds [sec_mda · as of 2026-08-07].
Sources: News · SEC MD&A · Generated September 26, 2026 · How we verify sources →
Run Entera Bio Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Entera Bio Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.68 · 0% dilution
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 0.4%
- Days to cover
- 1.1
- Shares short
- 192,781
- Daily short volume (Jun 9, 2026)
- 32.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Entera Bio Ltd.?
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing oral peptide therapies, with a lead program (EB613) in Phase 3 for osteoporosis and a recent $275M private placement extending its cash runway into 2030.
What is Entera Bio Ltd.'s lead drug candidate?
Entera Bio Ltd.'s most advanced tracked candidate is eb612 (Phase 2) for Hypoparathyroidism.
Who is the CEO of Entera Bio Ltd.?
Ms. Miranda J. Toledano M.B.A. is the chief executive officer of Entera Bio Ltd. (ENTX).
Where is Entera Bio Ltd. headquartered?
Entera Bio Ltd. (ENTX) is headquartered in Jerusalem, Israel.
What therapeutic areas does Entera Bio Ltd. focus on?
Entera Bio Ltd. develops therapies across Oncology, Metabolic, Dermatology, Musculoskeletal, Gastroenterology, Endocrinology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.